From: Sublingual sufentanil after orthopaedic and abdominal surgery: long-term outcome and safety
Age (in years) | |
Median | 67 |
Maximum | 87 |
Minimum | 32 |
Gender (m/f) | |
Female | 45 (56.3%) |
Male | 35 (43.8%) |
BMI (kg/m2) | |
Mean (± SDT) | 29.1 (± 5.9) |
Surgery | |
Knee joint arthrosis | n = 71 (88.8%) |
Abdominal surgery | n = 9 (11.3%) |
ASA (American Society of Anesthesiologists) | |
ASA I | n = 7 (8.8%) |
ASA II | n = 58 (72.5%) |
ASA III | n = 13 (16.3%) |
NYHA (New York Heart Association) | |
NYHA I | n = 44 (55%) |
NYHA I | n = 32 (40%) |
NYHA III | n = 1 (1.3%) |
Chronic pain-medication | |
WHO I | n = 20 (25%) |
WHO II/III | n = 11 (13.8%) |
Peri-operative hypnotics | |
TIVA with propofol | n = 15 (18.8%) |
Balanced anaesthesia | n = 32 (40%) |
Other (including spinal anaesthesia) | n = 33 (41.3%) |
Intraoperative PONV-prophylaxis | |
Dexamethasone | n = 39 (48.8%) |
Ondansetrone | n = 33 (41.3%) |
Intraoperative crystalloids (in ml) | |
Mean (± SDT) | 1667 (± 706) |
Patients with intraoperative catecholamines | n = 15 (18.8%) |
Patients with PONV | n = 6 (7.5%) |